AstraZeneca is anticipated to gain from potential negotiations for lighter tariffs between the U.K. and the U.S., which may improve its performance relative to European pharmaceutical stocks.
AstraZeneca's Enhertu showed improved response rates in biliary tract cancer patients, outperforming Compass Therapeutics' tovecimig, which had a 17.1% response rate with chemotherapy.
AstraZeneca's diabetes drug Farxiga faces competition from Boehringer Ingelheim's Jardiance, which reported a 6.1% increase in 2024 revenues.
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.